Industry

DUBLIN–(BUSINESS WIRE)–The “Contract Pharmaceutical Manufacturing Market, by Service Type, by Molecule Type, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Pharmaceutical companies are now pushing hard to reduce overall manufacturing and research costs by outsourcing various processes related to research, development and manufacturing. … [Read more…]

Health economics study estimates significant savings for England’s NHS OXFORD, England–(BUSINESS WIRE)–#AIH–A health economic study performed by NHS England’s Oxford Academic Health Science Network (AHSN) showed that Perspectum’s LiverMultiScan – an artificial intelligence-enhanced, noninvasive liver health diagnostic tool – is a cost-effective alternative to painful, invasive liver biopsies for monitoring disease activity and treatment response … [Read more…]

LONDON–(BUSINESS WIRE)–All Seas Capital Fund I (“All Seas Capital”), a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, announces a significant minority investment in Zimmer MedizinSysteme (“Zimmer” or the “Company”), one of the leading manufacturers of physiotherapy and aesthetics devices. A German family run business with over 50 … [Read more…]

ATLANTA–(BUSINESS WIRE)–#Biotech–Axion BioSystems today announces Maestro TrayZ, an innovative, live-cell analysis platform designed for high-throughput drug development and therapeutic discovery. The new system—featuring a slim multiplate tray design that allows for modular scalability and fits comfortably inside an incubator—joins Axion’s growing suite of next-generation Maestro products and offers a flexible, affordable option for noninvasive, label-free … [Read more…]

Positive results from Phase 2 NASH Trial (DESTINY-1) for PXL065 reported: Primary efficacy endpoint met: PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content at 36-weeks for all doses Paired liver biopsies confirmed strong improvement of fibrosis and other parameters PXL065 was observed to be safe and well tolerated with … [Read more…]

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland & BOSTON–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced it will publish half-year 2022 financial and operating results on Tuesday, September 27, 2022. Management will host a webcast to discuss … [Read more…]

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose-dependent reduction of all biomarkers related to fibrogenesis and fibrosis risk scores; improvement seen … [Read more…]

SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Company has successfully got listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE), making InnoCare the double-listed biotechnology company on the Hong Kong Stock Exchange (HKEx) and … [Read more…]

  NASHVILLE, Tenn.–(BUSINESS WIRE)–Yesterday, the U.S. District Court for the District of Columbia issued an opinion and final appealable order denying the request made by the U.S. Department of Justice and the States of New York and Minnesota for the Court to enjoin UnitedHealth Group Incorporated (NYSE: UNH) (“UnitedHealth Group”) from acquiring Change Healthcare Inc. … [Read more…]